Of interest, the dose of AZA observed to induce a CD8+ T cell response in this study is approximately one-half that utilized in the treatment of patients with de novo AML or myelodysplasia, consistent with the hypothesis that the observed reduction in relapse is consequent upon manipulation of the alloreactive response. The gene discussed is CD8A; the disease is Myelodysplasia.